Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Adjuvanted and Unadjuvanted Quadrivalent Seasonal Influenza Vaccines in Healthy Adults
NCT03945825Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2019
- Primary completion
- Sep 2020
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AF03 and delta inulin + CpG55.2 in influenza (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Local and Systemic Solicited Reactogenicity Events, Adverse Events and 5 more. Started Jun 2019; status: completed.
02
Drugs
AF03delta inulin + CpG55.2
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03945825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945825.